X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 51 filers reported holding X4 PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $69,991 | +123.0% | 36,078 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $31,388 | -12.4% | 36,078 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $35,825 | -64.2% | 36,078 | -38.6% | 0.00% | -50.0% |
| Q3 2022 | $100,000 | -42.5% | 58,760 | -67.3% | 0.00% | -60.0% |
| Q2 2022 | $174,000 | -29.6% | 179,963 | +27.7% | 0.01% | -16.7% |
| Q1 2022 | $247,000 | -54.8% | 140,963 | -40.9% | 0.01% | -53.8% |
| Q4 2021 | $546,000 | -61.4% | 238,566 | -10.8% | 0.01% | -66.7% |
| Q3 2021 | $1,416,000 | -33.6% | 267,582 | -18.5% | 0.04% | -43.5% |
| Q2 2021 | $2,133,000 | -19.7% | 328,209 | +6.4% | 0.07% | -31.0% |
| Q1 2021 | $2,657,000 | +372.8% | 308,561 | +253.2% | 0.10% | +376.2% |
| Q4 2020 | $562,000 | +8.1% | 87,364 | +13.8% | 0.02% | -32.3% |
| Q3 2020 | $520,000 | +207.7% | 76,765 | +384.6% | 0.03% | +106.7% |
| Q4 2019 | $169,000 | – | 15,840 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |